CAR T-Cell far a Koriya
Kuna son yin rajista don CAR T-Cell far a Koriya?
Yi haɗi tare da mu don ƙarshen sabis na sabis.
South Korea is paying a lot of attention to CAR T-cell therapy, which is a new kind of immunotherapy that has made a lot of progress. It involves changing the genes of a patient’s own T cells so they can make chimeric antigen receptors (CARs), which can find cancer cells and kill them. South Korea has done a lot of research and development on CAR T cell therapy, with a number of clinical trials and treatment centres devoted to this new method. CAR T cell far has been successful in South Korea because of the country’s healthcare system and technological knowledge. This has given patients with cutar kansa hope and paved the way for more personalized cancer treatments in the region.
CAR T-Cell far a Koriya - Ci gaban kwanan nan
Yuni 2023: CAR T-cell far ya zama sabuwar hanyar magance ciwon daji. Ya canza yadda muke yaƙar kansa daban-daban. A cikin 'yan shekarun nan, Koriya ta Kudu ta sami ci gaba mai yawa a wannan fanni, wanda ya nuna yadda take sadaukar da kai ga nazari da sababbin ra'ayoyi. Wannan yanki zai yi magana game da wasu sabbin abubuwan da ke faruwa a ciki CAR T-cell far a Koriya. Za a mayar da hankali ne kan sauye-sauyen da suka sa Koriya ta Kudu ke kan gaba a wannan fanni.
Gwaje-gwaje na asibiti da Yarda da Ka'ida: Koriya ta Kudu ta ci gaba da yin gwaje-gwaje na asibiti don maganin CAR T, yana haifar da yanayi wanda ke ƙarfafa ƙirƙira da kulawa da ke mayar da hankali ga mai haƙuri. Kasar ta kasance a sahun gaba wajen gwajin maganin cututtukan da suka shafi jinin jini da kuma tarkacen ciwace-ciwacen daji da dai sauransu. Musamman ma, gwaje-gwajen asibiti sun nuna sakamako mai kyau, wanda ya haifar da hanyoyin kwantar da hankali na CAR T da gwamnati ta amince da su don wasu amfani.
Haɓaka Sabbin Gine-ginen CAR: Masu bincike da masana kimiyya a Koriya ta Kudu sun yi aiki tuƙuru don yin sabbin gine-ginen CAR waɗanda ke sa maganin CAR T ya fi inganci da aminci. Wannan ya haɗa da inganta yadda ake yin masu karɓar antigen na chimeric ta yadda ƙwayoyin CAR T za su iya samun mafi kyau, kunnawa, da kuma kasancewa cikin ciwace-ciwacen daji. Waɗannan canje-canjen sun haifar da ingantattun sakamakon jiyya da ƙarancin sakamako masu illa.
Haɗin Magunguna: Masu binciken Koriya ta Kudu sun kuma duba yuwuwar hada maganin tantanin halitta ta CAR T tare da wasu nau'ikan jiyya, kamar masu hana wuraren bincike na rigakafi da hanyoyin kwantar da hankali. Masu bincike suna son inganta ƙimar amsawa da shawo kan matsalolin da nau'ikan ciwace-ciwacen daji ke haifar da su da kuma yadda suke ɓoye daga tsarin rigakafi.
Masana'antu da Kasuwanci: Koriya ta Kudu ta sami ci gaba mai yawa wajen ƙirƙirar matakai don yin jiyya na CAR T masu ƙarfi kuma ana iya haɓaka su. Hakan ya sa aka sa wadannan magunguna a kasuwa ana amfani da su da yawa, wanda hakan ya sa masu bukatar su samu sauki.
Koriya ta Kudu yanzu ita ce kan gaba a duniya a fannin maganin ƙwayoyin cuta na CAR T. Ya yi haka ta hanyar amfani da basirar bincike, ilimin asibiti, da tsarin tsari don samun ci gaba mai ban mamaki a wannan yanki. Ƙullawar ƙasar don ƙirƙira da yanayin binciken haɗin gwiwarta ya haifar da ƙirƙirar sabbin gine-ginen CAR, gwajin gwaji na asibiti mai nasara, da kasuwancin waɗannan hanyoyin kwantar da hankali. Wadannan sababbin abubuwan da suka faru suna da damar da za su canza yadda ake magance ciwon daji da kuma inganta sakamakon haƙuri, ba kawai a Koriya ta Kudu ba amma a duk faɗin duniya. Koriya ta Kudu na iya yin babban tasiri a kan makomar CAR T cell jiyya yayin da filin ke ci gaba da canzawa.
CAR T-cell therapy, developed by Novartis and marketed under the brand name Kymriah, is currently being provided by the CAR T-cell Therapy Center to patients under the age of 25 who suffer from B-cell acute lymphoblastic leukaemia or diffuse large B-cell linzoma. In addition, patients who have refractory diffuse large B-cell lymphoma are the focus of clinical trials being conducted for CRCO1, which was developed by a company based in Korea called Curocell. In addition, because Korea is widely recognised as the CAR T-cell Therapy hub in the world, clinical trials for the CAR T-cell therapy developed by Janssen are also currently being conducted for patients who have relapsed or refractory Multi myeloma.
Kafin fara jiyya, ana buƙatar marasa lafiya da ke jurewa CAR T-cell far don daidaita ƙoƙarin su tare da sassan asibitoci daban-daban. Don zama mafi yawan takamaiman, adadi mai yawa na kwararru a cikin filayen da ke da alaƙa da cuta sosai ga cututtukan zuciya, masu ilimin cututtukan fata, da kuma kulawa mai zurfi suna da hannu bayan jiyya.
Cibiyar jiyya ta CAR T-cell a halin yanzu tana shiga cikin "Bincike-daidaitacce Asibitin R&D Project" na Ma'aikatar Lafiya da Jin Dadin Jama'a, kuma ana sa ran zama cibiyar kula da kwayar cutar kwayar cutar da ke jagorantar babban matakin maganin tantanin halitta da takamaiman magani na haƙuri. ga marasa lafiya oncology na hematological. Ma'aikatar lafiya da walwala ce ta fara aikin.
Wadanne kamfanoni ne ke da hannu wajen kera CAR T-Cells a Kudancin Koriya?
A Nuwamba 16, 2022, ViroMed, wani kamfani na Koriya, ya sanar da wani shiri na samar da maganin CAR-T. Fasahar inganta kwayoyin halittar CAR, fasahar samar da vector, da fasahar ex vivo don canja wurin kwayoyin halitta da yaduwar kwayar halitta duk suna samuwa ga kasuwanci don haɓaka magungunan CAR-T. Bayan sayar da "VM801," fasahar CAR-T ta ViroMed, ga US Bluebird Bio akan biliyan 56.8 ya ci nasara a watan Disamba 2015, kamfanin yana shirin samar da samfuran CAR-T guda uku.
Bugu da ƙari, AbClon yana haɓaka maganin ciwon daji na jini bisa fasahar da ƙungiyar bincike ta jagoranci Farfesa Jung Jun-ho na Jami'ar Kasa ta Seoul a watan Fabrairu, wanda ya fi aminci fiye da magungunan CAR-T na yanzu. An san fasahar ƙungiyar don bambance kanta daga magungunan yanzu ta hanyar rage yawan ƙwayar cuta ta cytokine (CRS), mummunan sakamako na magungunan CAR-T wanda zai iya haifar da hauhawar jini, zazzabi, har ma da mutuwa ga marasa lafiya.
Don cire shi, Green Cross Cell, wani reshen Green Cross, yana dubawa da tabbatar da masu neman magani na CAR-T don ingantaccen maganin kansa. Kamfanin ya yi niyyar gudanar da bincike don fara gwajin gwajin asibiti a shekara mai zuwa. Tun lokacin da aka nada Son Ji-woong a matsayin shugaban Sashin Kasuwancin Kimiyyar Rayuwa a watan Fabrairu, LG Chem ya ce yana tunanin aiwatar da fasahar da ke da alaƙa da magungunan CAR-T, tare da samar da magungunan ciwon sukari da magungunan rigakafi na rigakafin cutar kansa. mahimmin aikin R&D na kamfani.
Curocella, Farfagandar fasahar kere-kere ta Koriya ta Kudu wadda ta fara aikin farfaɗowar ƙwayar cuta ta CAR-T, tana shirin ƙaddamar da gwajin gwaji na wani sabon labari na maganin ƙwayoyin cuta na CAR-T wanda ke da alaƙa da ciwon daji na jini da kuma ciwace-ciwace.
Curocell kwanan nan ya ƙaddamar da aikace-aikacen IND don gwaji na asibiti na maganin tantanin halitta na CAR-T a Koriya, kuma babban jami'in kamfanin Kim Gun-soo ya shaida wa jaridar Maeil Business Newspaper cewa ana sa ran Ma'aikatar Abinci da Kare Magunguna za ta amince da shi a wannan watan.
Curocell ya riga ya kulla kawance tare da Cibiyar Kiwon Lafiya ta Samsung don fara gwajin da zarar an amince da shi, a cewar Kim, wanda ke fatan samun maganin cutar kansa ga marasa lafiyar Koriya da wuri-wuri.
CAR-T is an immunotherapy that is programmed to identify and destroy cancer cells. T cells from a single patient are genetically engineered in a lab to produce cancer-specific chimeric antigen receptors in order to create this treatment. After that, the cancer-fighting cells are re-infused into the patient’s body.
An nuna cewa maganin tantanin halitta na CAR-T ya fi nasara fiye da kowane maganin ciwon daji da ake samu a halin yanzu. A cewar Kim, duk da kasawa da sauran hanyoyin kwantar da hankali, kashi 82 cikin 32 na masu fama da cutar sankarar bargo da kashi 36-XNUMX na marasa lafiyar lymphoma sun zama marasa ciwon daji tare da jiko guda ɗaya na CAR-T.
Duk da haka, sakamakon babban inganci na CART yana iyakance ga maganin ƙwayoyin cutar kansa na jini kuma ba za a iya yin kwafi ga ciwace-ciwacen ciwace-ciwacen daji ba saboda mai karɓar maganin rigakafi (PD-1) wanda aka samu a cikin ƙwayoyin rigakafin marasa lafiya masu ƙarfi, wanda ke hana ayyukan ƙwayoyin cuta.
Mai karɓar wurin duba garkuwar jiki yana aiki azaman birki akan ikon sel na rigakafi. Lokacin da masu karɓar wuraren bincike na rigakafi kamar PD-1 suka wuce gona da iri, ikon sel na rigakafi na cire ƙwayoyin kansa yana raguwa, yana sa cire ƙari ya fi wahala.
Fasahar Curocell's OVIS (Nasarar Ciwon Immune Immune) ta shawo kan wannan ƙuntatawa, yana ba da damar yin amfani da maganin ƙwayoyin cuta na CAR-T don magance ciwace-ciwace. OVIS fasaha ce ta injiniya ta kwayoyin halitta wacce ke amfani da gyare-gyaren kwayoyin halitta na ƙwayoyin rigakafi don murkushe mai karɓar RNA (ribonucleic acid). Wani sabon maganin tantanin halitta na CAR-T da aka aiwatar da wannan fasaha ya fi nasara fiye da jiyya na CAR-T na yanzu a cikin ƙirar dabba, a cewar Kim.
Sai dai don maganin Curocell, babu ɗayan magungunan CAR-T da ke samuwa a halin yanzu ko a cikin gwaji na asibiti da zai yi niyya ga ciwon daji na jini da ciwace-ciwacen daji, a cewar Curocell.
Yadda ake neman CAR T-Cell far a Koriya?
Aika rahoton likitan ku zuwa info@cancerfax.com ko kuma WhatsApp su +1-213 789-56-55. Aika rahotanni masu zuwa don ra'ayi da kimantawa:
1) Takaitawar likitanci
2) Sabbin rahotannin jini
3) Biopsy
4) Sabbin Binciken PET
5) Biopsy marrow biopsy (Idan akwai)
6) Duk wani rahoton da ya dace da dubawa
Da zarar ƙungiyarmu ta karɓi rahoton ku na likita, muna bincika su kuma mu aika zuwa asibitocin da ke yin maganin CAR T-Cell tare da irin wannan nau'in ciwon daji da alamar. Muna aika rahotanni zuwa ga kwararrun da abin ya shafa kuma mu sami ra'ayinsa. Binciken rahoton yana biye da shawarwarin bidiyo akan layi tare da gwani. Muna kuma samun kiyasi daga asibiti kan cikakken magani. Wannan yana taimaka muku wajen tsara duk tsawon lokacin jiyya.
Da zarar ka yanke shawarar ziyartar magani, mun shirya wasiƙar takardar visa ta likita da sauran takaddun da suka dace daga asibiti. Muna kuma taimaka muku da jagora wajen neman takardar izinin likita zuwa ofishin jakadancin Koriya. Da zarar an shirya biza za mu taimaka da shiryar da ku don shirya tikitin tafiya da jirgin sama. Muna kuma shirya otal ɗin ku da gidan baƙi, idan an buƙata a Kudancin-Koriya. Bayan isa birnin jiyya wakilin mu zai maraba da ku a filin jirgin sama.
Wakilinmu zai shirya wa likita alƙawarin kuma ya cika muku ƙa'idodin rajista da suka dace. Zai kuma taimaka muku da shigar ku asibiti da sauran taimako da tallafi na gida waɗanda ake buƙata. Bayan an gama jinyar za mu shirya tuntubar ku tare da likitan jinya.
Manyan asibitoci don CAR T-Cell far a Koriya
Asan Medical Center
Cibiyar kula da lafiya ta Asan ta Koriya ta Kudu ta kasance kan gaba wajen yin amfani da sabbin fasahohi don magance cutar kansar jini, da nufin inganta sakamakon marasa lafiya da ingancin rayuwa. Cibiyar ta saka hannun jari a cikin fasahohin zamani kamar jerin masu zuwa (NGS) don ingantaccen taswirar kwayoyin cutar ciwace-ciwacen daji, wanda ke ba da damar kula da kowane majiyyaci daban-daban. Cibiyar Kiwon Lafiya ta Asan ta kuma kara sabbin jiyya, irin su CAR T cell therapy, wanda ke amfani da tsarin garkuwar marasa lafiya wajen kai hari ga kwayoyin cutar kansa. Waɗannan kayan aikin sun canza yadda ake samun cutar kansar jini, bin diddigin, da kuma bi da su, suna ba marasa lafiya sabon bege da kuma sa Cibiyar Kiwon Lafiya ta Asan ta zama jagora a yaƙi da cutar kansar jini.
Menene farashin CAR T-Cell far a Koriya?
Farashin CAR T-Cell a Kudancin-Koriya yana farawa daga $ 450,000 USD kuma yana iya kaiwa har $ 500,000 USD dangane da nau'i da girman cutar da nauyinta a jiki. Yana da mahimmanci a tuna cewa wannan ƙididdiga ta gaba ɗaya ce kawai kuma takamaiman yanayi na iya canzawa. Madaidaicin nau'in maganin CAR-T, daɗaɗɗen hanya, farashin asibiti, kulawar tallafi, da ƙarin gwaje-gwajen bincike duk masu canji ne waɗanda zasu iya shafar farashi. Don sarrafa farashin da ke da alaƙa da maganin tantanin halitta na CAR-T, an shawarci marasa lafiya su yi magana da ƙwararrun kiwon lafiya kuma su duba ɗaukar inshora ko shirye-shiryen taimakon kuɗi.
Menene maganin T-Cell CAR?
Chimeric antigen receptor T-cell far, wanda aka fi sani da CAR T-cell therapy, wani maganin rigakafi ne mai rushe ƙasa wanda ya canza gaba ɗaya yadda ake bi da ciwon daji. Yana ba wa marasa lafiya da wasu cututtukan daji fata waɗanda aka gani a baya a matsayin ba za a iya warkewa ba ko kuma suna da ƴan hanyoyin warkewa.
Maganin ya haɗa da yin amfani da ƙwayoyin rigakafi na majiyyaci-musamman, ƙwayoyin T-da kuma gyara su don inganta ƙarfin su don ganowa da lalata ƙwayoyin cutar kansa. Don yin wannan, ana ba da ƙwayoyin T na ƙwayoyin cuta na chimeric antigen receptor (CAR), wanda ke ba su ikon kai hari kan wasu sunadaran sunadaran, ko antigens, a saman ƙwayoyin cutar kansa.
An fara cire ƙwayoyin T daga majiyyaci, sannan a canza su ta hanyar kwayoyin halitta don bayyana CAR. A cikin dakin gwaje-gwaje, waɗannan sel da aka canza suna haɓaka don samar da adadi mai yawa na ƙwayoyin CAR T, sannan a mayar da su cikin jinin mara lafiya.
Da zarar sun shiga cikin jiki, ƙwayoyin CAR T suna samun ƙwayoyin kansa waɗanda ke bayyana antigen da ake so, suna manne musu, kuma suna haifar da amsawar rigakafi. Kwayoyin CAR T da aka kunna suna yaduwa kuma suna kai hari kan ƙwayoyin cutar kansa, suna kashe su.
Ta yaya maganin C-T-Cell ke aiki?
Lokacin da aka yi amfani da shi don magance wasu cututtuka na jini kamar m lymphoblastic cutar sankarar bargo (ALL) da takamaiman nau'i na lymphoma, CAR T-cell far ya nuna sakamako na musamman. Ya haifar da ƙima mai ƙima da kuma a wasu marasa lafiya, har ma da dawwamammen gafara.
CAR T-cell far, duk da haka, hanya ce mai ƙwarewa kuma ta musamman wacce za ta iya samun haɗari da illa. Cytokine saki ciwo (CRS), wani tartsatsi na rigakafi dauki wanda zai iya haifar da mura-kamar bayyanar cututtuka da kuma, a cikin matsananci yanayi, gabobin jiki gazawar, na iya dandana daga wasu mutane. Haka kuma an sami rahotanni game da illar cutar jijiya, duk da haka ana iya warkewa akai-akai.
Duk da waɗannan matsalolin, CAR T-cell far wani gagarumin ci gaba ne a cikin yaƙi da ciwon daji kuma yana nuna babban damar nan gaba. Binciken na yanzu yana mai da hankali kan haɓaka ingancinsa da bayanin martabarsa tare da faɗaɗa amfaninsa zuwa nau'ikan ciwon daji daban-daban. CAR T-cell far yana da ikon canza fuskar maganin ciwon daji da ba marasa lafiya a ko'ina sabon bege tare da ci gaba.
hanya
Tsarin jiyya na CAR-T, wanda ke ɗaukar makonni kaɗan, ya ƙunshi matakai da yawa:
Ana fitar da ƙwayoyin T daga jinin ku ta amfani da bututu da aka sanya cikin jijiya ta hannu. Wannan yana ɗaukar sa'o'i biyu.
Kwayoyin T ana jigilar su zuwa wani wuri inda suke yin gyare-gyaren kwayoyin halitta don zama ƙwayoyin CAR-T. Makonni biyu zuwa uku sun wuce duk wannan.
Ana sake dawo da ƙwayoyin CAR-T cikin jinin ku ta ɗigo. Wannan yana buƙatar sa'o'i da yawa.
Kwayoyin CAR-T sun yi niyya kuma suna kawar da kwayoyin cutar kansa a cikin jiki. Bayan karbar maganin CAR-T, za a sa ido sosai.
Wane nau'in ƙwayoyin kansa ne za a iya bi da su tare da CAR-T Cell Therapy?
Only patients with adult B-cell non-lymphoma Hodgkin’s or pediatric m lymphoblastic cutar sankarar bargo who have already tried two unsuccessful conventional therapies can currently use CAR T-cell therapy products that have received FDA approval. However, CAR T-cell therapy is now being tested in clinical studies as a first or second-line treatment for adult lymphoma and pediatric acute lymphoblastic leukemia. Recently, some of the studies have shown remarkable successes in cases of solid tumors too like glioblastoma, gliomas, liver cancer, lung cancer, GI cancer, pancreatic cancer and baka ciwon daji.
Don kammala
Wannan yana wakiltar ci gaba mai mahimmanci a cikin kula da cutar sankarar bargo da B-cell lymphoma. Bugu da ƙari, yana ba da bege ga waɗanda aka yi hasashen rayuwarsu za ta wuce watanni shida kacal. Yanzu da muka gano hanyoyin juriya kuma mun ƙirƙiri ƙarin dabaru don yaƙar su, nan gaba yana da alama ya fi dacewa.
Tuntuɓi ƙwararrun ƙwararrun masu ba da lafiya a nan a Faxar Cancer don shawarwari na kyauta don tsara tsarin kulawa mai dacewa don bukatun ku na kiwon lafiya. Da fatan za a aika da rahoton likitan ku zuwa info@cancerfax.com ko WhatsApp zuwa + 1 213 789 56 55.
Menene fa'idodin CAR-T Cell Therapy?
The main benefit is that CAR T-cell therapy only requires a single infusion and often only requires two weeks of inpatient care. Patients with ba Hodgkin lymphoma and pediatric leukemia who have just been diagnosed, on the other hand, typically need chemotherapy for at least six months or more.
Amfanin maganin CAR T-cell, wanda shine ainihin magani mai rai, na iya dawwama shekaru da yawa. Idan kuma lokacin da sake dawowa ya faru, ƙwayoyin za su iya ganowa da kuma kai hari ga ƙwayoyin cutar kansa saboda suna iya rayuwa a cikin jiki na tsawon lokaci.
Kodayake bayanin yana ci gaba, kashi 42 cikin 19 na marasa lafiya na lymphoma manya waɗanda suka yi amfani da CD15 CAR T-cell magani har yanzu suna cikin gafara bayan watanni XNUMX. Kuma bayan watanni shida, kashi biyu bisa uku na marasa lafiya da ke fama da cutar sankarar mahaifa mai tsanani na lymphoblastic na yara har yanzu suna cikin gafara. Abin takaici, waɗannan majiyyatan suna da ciwace-ciwacen ciwace-ciwacen daji waɗanda ba a samu nasarar yi musu magani ta amfani da ƙa'idodin kulawa na gargajiya ba.
Wane nau'in marasa lafiya ne za su zama masu karɓa na CAR-T Cell Therapy?
An gwada marasa lafiya tsakanin shekaru 3 zuwa shekaru 70 tare da maganin CAR T-Cell don nau'in ciwon daji na jini daban-daban kuma an gano yana da tasiri sosai. Cibiyoyi da yawa sun yi iƙirarin ƙimar nasara fiye da 80%. Mafi kyawun ɗan takarar don CAR T-cell far a wannan lokacin shine ƙaramin yaro tare da cutar sankarar lymphoblastic mai tsanani ko kuma balagagge tare da lymphoma mai tsanani na B-cell wanda ya riga ya sami layi biyu na rashin tasiri.
Kafin ƙarshen 2017, babu wani tsarin kulawa da aka yarda da shi ga marasa lafiya waɗanda suka riga sun shiga cikin layi biyu na jiyya ba tare da samun gafara ba. Magani kawai da FDA ta amince da shi wanda ya zuwa yanzu ya tabbatar da cewa yana da fa'ida sosai ga waɗannan marasa lafiya shine CAR T-cell far.
Yaya tasiri na CAR-T Cell far?
CAR T-cell far ya kasance mai tasiri sosai wajen magance wasu nau'in ciwon daji na jini, kamar cutar sankarar bargo na lymphoblastic (ALL) da lymphoma ba Hodgkin. A cikin gwaje-gwaje na asibiti, ƙimar amsawar sun kasance da kyau sosai, kuma yawancin marasa lafiya sun shiga cikin cikakkiyar gafara. A wasu lokuta, mutanen da suka gwada kowane magani sun sami gafara na dindindin ko ma yiwuwar warkewa.
Ɗaya daga cikin mafi kyawun abubuwa game da maganin CAR T-cell shine cewa yana kai hari ga ƙwayoyin da suka dace. Masu karɓar CAR waɗanda aka ƙara zuwa ƙwayoyin T suna iya samun takamaiman alamomi akan ƙwayoyin cutar kansa. Wannan yana ba da damar ba da magani da aka yi niyya. Wannan hanyar da aka yi niyya tana cutar da ƙwayoyin lafiya kaɗan gwargwadon yuwuwa kuma tana rage haɗarin illolin da ke zuwa tare da jiyya na gargajiya kamar chemotherapy.
Amma yana da mahimmanci a tuna cewa CAR T-cell far har yanzu wani sabon yanki ne wanda har yanzu yana canzawa. Masu bincike da likitoci suna aiki tuƙuru don magance matsaloli kamar tsadar tsada, yuwuwar sakamako mai tsanani, da gaskiyar cewa yana aiki ne kawai ga wasu nau'ikan cutar kansa.
A ƙarshe, maganin CAR T-cell ya nuna hanya ce mai nasara sosai don magance wasu nau'in ciwon daji na jini. Ko da yake hanya ce mai ban sha'awa da ƙarfi, ana buƙatar ƙarin nazari da gwaje-gwaje na asibiti don inganta shi da nemo sababbin hanyoyin amfani da shi. CAR T-cell far na iya canza yadda ake bi da kansa kuma ya sa abubuwa su zama mafi kyau ga mutane a duk faɗin duniya idan ta ci gaba da samun gyaruwa.
Ma'aunin haɗawa & keɓancewa
Ka'idodin haɗawa don maganin T-cell CAR:
1. Marasa lafiya tare da CD19+ B-cell Lymphoma (Aƙalla 2 kafin hadewar chemotherapy)
2. Yayi shekaru 3 zuwa 75
3. ECOG ci ≤2
4. Matan da ke da damar haihuwa dole ne a yi gwajin ciki na fitsari kuma an tabbatar da rashin kyau kafin magani. Duk marasa lafiya sun yarda su yi amfani da ingantattun hanyoyin hana haihuwa a lokacin gwajin har zuwa bin diddigin na ƙarshe.
Sharuɗɗan keɓancewa don CAR T-cell far:
1. Hawan jini a cikin kwakwalwa ko suma
2. Rashin numfashi
3. Yada yaduwar jijiyoyin cikin jini
4. Hematosepsis ko Ciwo mai aiki mara ƙarfi
5. Rashin sarrafawa ciwon sukari
CAR T-Cell magungunan da USFDA ta amince da su
B-cell precursor m lymphoblastic cutar sankarar bargo, koma baya ko refractory yaduwa babban B-cell lymphoma
Cikakken ƙimar amsawa (CR):> 90%
Saukewa: CD19
Farashin: $ 475,000
Lokacin amincewa: Agusta 30, 2017
Mai sake dawowa ko refractory yana yaduwa babban lymphoma na B-cell, relapsed ko refractory follicular cell lymphoma
Cikakkun martanin Cikakkun Amsa na Ciwon lymphoma ba Hodgkin (CR): 51%
Saukewa: CD19
Farashin: $ 373,000
Lokacin amincewa: Oktoba 2017, 18
Maimaitawa ko mai jujjuyawa yana yaduwa babban lymphoma na B-cell
Mantle cell lymphoma Cikakken ƙimar amsawa (CR): 67%
Saukewa: CD19
Farashin: $ 373,000
Lokacin da aka amince: Oktoba 18, 2017
Maimaitawa ko mai jujjuyawa yana yaduwa babban lymphoma na B-cell
Cikakken ƙimar amsawa (CR): 54%
Saukewa: CD19
Farashin: $ 410,300
Lokacin da aka amince: Oktoba 18, 2017
Maimaitawa ko Mai Rarraba Multiple Myeloma
Cikakken ƙimar amsawa: 28%
Saukewa: CD19
Farashin: $ 419,500
An amince da shi: Oktoba 18, 2017
Menene illolin maganin CAR-T?
A ƙasa an ambata wasu daga cikin illolin maganin CAR T-Cell.
- Ciwon saki na cytokine (CRS): The most prevalent and possibly significant side effect of CAR T-cell treatment is Ciwon saki na cytokine (CRS). The flu-like symptoms, including fever, exhaustion, headaches, and muscle pain, are brought on by the modified T cells’ production of cytokines. In extreme circumstances, CRS may result in a high temperature, hypotension, organ failure, and even potentially fatal consequences.
- Gubar Neurological: Wasu marasa lafiya na iya haifar da sakamako masu illa na jijiyoyi, wanda zai iya bambanta da tsanani daga ƙananan alamu kamar ruɗani mai sauƙi da rashin fahimta zuwa mafi tsanani kamar seizures, delirium, da encephalopathy. Bayan jiko na T-cell na CAR, yawan guba na jijiyoyin jiki yana faruwa akai-akai a cikin makon farko.
- Cytopenia: Maganin CAR T-cell zai iya haifar da ƙananan ƙwayoyin jini, irin su anemia (ƙananan ƙwayar jinin jini), neutropenia (ƙananan ƙwayar jinin jini), da kuma thrombocytopenia (ƙananan adadin platelet). Cututtuka, zub da jini, da gajiyawa suna cikin haɗarin da waɗannan cytopenia za su iya tsananta.
- Cututtuka: CAR T-cell therapy's ƙwanƙwasa ƙwayoyin rigakafi masu lafiya yana ƙara haɗarin ƙwayoyin cuta, ƙwayoyin cuta, da fungal. Domin hana kamuwa da cututtuka, ana iya buƙatar majiyyata a sa ido sosai kuma a ba su magunguna na rigakafi.
- Tumor Lysis Syndrome (TLS): Bayan CAR T-cell far, yana yiwuwa a wasu yanayi a iya sakin adadin abubuwan da ke cikin tantanin halitta zuwa cikin jini saboda saurin kashe ƙwayoyin tumor. Wannan na iya haifar da rashin daidaituwa na rayuwa, kamar yawan potassium, uric acid, da matakan phosphate, wanda zai iya lalata kodan kuma ya haifar da wasu matsaloli.
- Hypogammaglobulinemia: Maganin CAR T-cell yana da yuwuwar rage ƙwayar ƙwayar cuta, wanda zai iya haifar da hypogammaglobulinemia. Wannan na iya sa kamuwa da cuta mai maimaitawa ya fi yuwuwa kuma yana kira don ci gaba da maye gurbin maganin rigakafi.
- Yawan Guba: CAR T-cell far yana da yuwuwar cutar da gabobin da dama, gami da zuciya, huhu, hanta, da koda. Wannan na iya haifar da gwaje-gwajen aikin koda mara kyau, al'amuran numfashi, matsalolin zuciya, da gwajin aikin hanta mara kyau.
- Hemophagocytic lymphohistiocytosis (HLH): Cutar da ba kasafai ba amma mai yiwuwa mai saurin kisa da ake kira hemophagocytic lymphohistiocytosis (HLH) na iya tasowa a sakamakon maganin CAR T-cell. Ya haɗa da wuce gona da iri na ƙwayoyin rigakafi, wanda ke haifar da mummunar lalacewar gabobin da kumburi.
- Hypotension da Riƙewar Ruwa: Sakamakon cytokines da ƙwayoyin CAR T suka saki, wasu marasa lafiya na iya haifar da ƙananan hawan jini (hypotension) da riƙewar ruwa. Don magance waɗannan alamomin, ana iya buƙatar matakan tallafi gami da ruwan jijiya da magunguna.
- Malignancin Sakandare: Rahotanni na malignancies na biyu da ke fitowa bayan maganin CAR T-cell sun wanzu, duk da ƙarancinsu. A halin yanzu ana gudanar da bincike kan yuwuwar kamuwa da cutar ta biyu da kuma haɗari na dogon lokaci.
Yana da kyau a tuna cewa ba kowane majiyyaci ne zai sami waɗannan illolin ba, kuma matakin hankalin kowane mutum zai bambanta. Don ragewa da rage girman waɗannan abubuwan da zasu iya haifar da illa, ƙungiyar likitocin suna bincikar marasa lafiya sosai kafin, lokacin, da kuma bayan maganin CAR T-cell.
Lokaci
Bincika ƙasa jimlar firam ɗin lokacin da ake buƙata don kammala aikin CAR T-Cell. Kodayake tsarin lokaci ya dogara da yawa akan nisan lab daga asibitin da ya shirya na CAR.
- Jarabawa & gwaji: mako guda
- Pre-treatment & T-Cell Tarin: mako guda
- Shirye-shiryen T-Cell & dawowa: makonni biyu zuwa uku
- 1st Tasirin bincike: makonni uku
- 2nd Tasirin Bincike: makonni uku.
Jimlar lokacin: 10-12 Makonni